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modiﬁes this relationship. We used contractual data from the National Longitudinal Study of Adolescent to
Adult health data spanning a 14 year period. We assessed the relationship between gateway drugs at baseline
(age 11–20 years) and drug use in adulthood using generalized estimating equation (GEE) regression models.
Gateways drugs used in early adolescence were signiﬁcantly associated with marijuana use, illegal drugs and
cocaine in older adolescence, but over time these relationships were not consistent in adulthood. Changes in
the pattern of psychoactive drug use were important predictors of drug use in adulthood. A history of higher
depressive symptomswas associated with higher frequencies of psychoactive drug use over time. Users of men-
tal health services in adolescence were less likely to use drugs in older adolescence and in adulthood. Relation-
ships between early drug use and later drug use in adulthood cannot be solely explained by the gateway
hypothesis. Collectively, adolescent drug prevention and treatment programs should apply theory-based and
evidence-proven multisectoral intervention strategies rather than providing a brief counseling on individual's
behaviors. This evidence should include understanding that changes in behavior should involve broader analyses
of the underlying social context for drug use and in particular the role of the community social norms in driving a
group's behaviors.
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Young people1. Introduction
The concept of “gateway hypothesis” has been studied since the
1970s (Kandel, 1975; Kandel and Faust, 1975) as the theory suggests
that an adolescent's early experimentation with alcohol or tobacco or
cannabis escalates to more addictive illicit drugs later in adulthood
(Lynskey et al., 2003). Most commonly used illicit substances include
heroin/opioids, cocaine and or amphetamines and their designer drug
analogs, considered illegal by the criminal justice system in the United
States and other jurisdictions. Early onset or drug experimentation has
been elaborated and characterized in distinct pathways in the substance
abuse and dependence literature. Overall, the theory has had mixed re-
sults showing both a link or sequence of licit drug use to illicit drug use
(Guxens et al., 2007; Guxens et al., 2007; Korhoene et al., 2010; Lessemsity, Department of Population
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1997; Golub and Johnson, 1994).
Although the concept has also been a subject of considerable schol-
arly and political discourse in western societies, a review of the litera-
ture often shows less consensus on research and policy relevance
among investigators. An earlier series of studies (Kandel, 1975; Kandel
and Faust, 1975; Kandel et al., 1992) among adolescents showed the
existence of a signiﬁcant and a clearly deﬁned sequence of drug use
onset starting with licit substances (alcohol, cigarette) and progression
to illicit drugs (cocaine, marijuana, methamphetamine, and heroin)
through adulthood. Recently, Kandel and Kandel (2014), have demon-
strated the GH with animal studies and their ﬁndings showed that use
of one drug enhances effects of the other drugs — a process hypothe-
sized as due to the priming of the neural circuitry of the brain.
Fergusson et al. (2006) analyzed a population-based data on cannabis
use and progression to other illicit drugs among a 25-year longitudinal
study of 1265 birth cohorts from Christchurch, New Zealand. The investi-
gators found strong evidence for causal model of GH, in which earlier use
of cannabis was hypothesized as causing increased use of other illicit
drugs. In addition, numerous prior studies have failed to disconﬁrm
causal links of gateway effects in human populations (Kandel, 2002;
Gundy and Rebellon, 2010; Morral et al., 2002). However, a cross-tp://creativecommons.org/licenses/by/4.0/).
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ground prevalence of the gateway drugs or their availability as the
major driving factor for drug use progression across countries analyzed.
Another study analyzing a sample of adolescents from South Florida
showed that marijuana gateway effect is contingent on context of age
(Gundy and Rebellon, 2010). In spite of these, it is still unclear the ex-
tent to which a cohort of adolescents at different developmental stages
experience gateway drug use (tobacco, alcohol, marijuana) as determi-
nants of later illicit drug use during and prior to adulthood.
Consistent with the theory, research in the substance abuse
literature has focused on age of onset of substance used as a proximate
determinant of future drug use and dependence in adulthood (Chen
et al., 2009; Behrendt et al., 2009; Trenz et al., 2012; Mayet et al.,
2012). Trenz et al. (2012) found early onset of alcohol at age 15 but
not cigarette or marijuana among adolescents as a risk factor for
injection drug use in adulthood. An earlier study by Chen et al. (2009),
reported clinical manifestation of drug dependence and other health
problems among adolescents' early onset (11–17 years) of drug use
compared with adult (18+) recent users. Likewise, Lynskey et al.,
report that among discordant twins, individuals starting cannabis use
before age 17 were at increased risk of illicit drug use and drug depen-
dence. Mayet et al. (2012) found that among 17-year olds participating
in a military exercise in France, initiating one drug increased the risk of
initiating the other drug use, consistent with the gateway theory.
However, the risk of an experimenter becoming a daily user of tobacco
was higher for initial tobacco users than cannabis. A recent follow-up
study byMayet et al. (2012) found daily tobacco use among adolescents
as strongly associated with cannabis initiation and other illicit drugs.
However, deviations to these patterns of drug use have been also ob-
served in studies and hypothesized to be linked to an underlyingmental
health condition of respondents (Degenhardt et al., 2010). One study of
cross national comparisons of 17 countries found prior drug use and age
of onset as the most dominant factors determining drug dependence
(Degenhardt et al., 2010). In addition, there were considerable varia-
tions of early onset of drug use among similar age cohorts in different
countries. Unfortunately the prospective relationship between early
drug onset in adolescence and drug use transition in adulthood was
not evaluated.
Although the evidence suggests that substance use dependencemay
also occur with the initial drug experimentation of commonly available
legal substances (Kirby and Barry, 2012), continual use over time may
increase the likelihood of developing risks for substance use disorders
(Deza, 2015) and other substance-related illnesses. In this regard,
Midanik et al. (2007), reported that simultaneous alcohol and cannabis
use was related to increased prevalence rates of other social conse-
quences including problem behaviors, alcohol dependence and depres-
sion. A twin-study of youngwomen by Agrawal et al. (2009), found that
women's initial use of tobacco and cannabis simultaneously was more
likely to experience higher rates of DSM IV cannabis abuse but not
dependence. The possibility of other addictive drugs (codeine and
other prescription drugs) and substances (hallucinogens, inhalants,
ecstasy, amphetamines) resulting in poor health sequelae due to initial
drug experimentation has been noted in some studies (Fairman, 2015;
Deza, 2015). This is important considering the extent of initial substance
use or use combinations could lead to more widespread illegal drugs or
addictive behaviors over time, replications of these ﬁndings in a nation-
ally representative sample of adolescents transitioning to adulthood are
needed to understand the continuum of progression of drug use over
the life course (from adolescence to adulthood).
Despite a great uncertainty about the gateway theory, with few
exceptions (Behrendt et al., 2009; Fergusson et al., 2006) there has been
remarkably less rigorous empirical assessment with a population-based
sample, prospectively assessing the impact of early drug use on later
drug use as well as related mental health conditions (depressive
symptoms). Data from longitudinal studies will allow for additional
questions to be explored including how changes in drug use over timefrom early adolescence to adulthood might be related to earlier onset of
druguse and apattern of individual druguse trajectories during transition
to adulthood. Sequence of drug initiation may be due to several factors
including effects of one drug use on another, familial and demographic
and psychosocial characteristics or a combination of different factors
(Guerra et al., 2000). In addition most of these studies did not control
for current substance use, a factor which is an important determinant
for fully understanding how earlier drug use or non-drug usemay change
over time from adolescence to young adulthood.
The aim of this study is to evaluate the impact of early substance use
on later illicit drug use while accounting for concurrent drug use over a
relatively longer period among a cohort of adolescents transitioning to
adulthood, and to determine the extent to which these relationships
conform to theGH.Our analyses here examine the relationship between
early gateway drug use and future illicit drug use among a cohort of
adolescents, and to determine whether causal or non-causal inferences
are warranted. We anticipate gateway drug use among our sample to
escalate to illicit drug use in adulthood and we expect this relationship
to be non-causal. Our hypothesis is that any gateway relationship in
adulthood reﬂects spurious effects of underlying depressive symptoms
and age as well as modifying inﬂuences of these factors (age and de-
pressive symptoms). Second, we were also interested in investigating
the relationship between early drug use onset in adolescence and
substance use in adulthood taking into account the existing concurrent
mental health status of individuals at each developmental stage. To the
extent that gateway associations to illicit drug use among older adoles-
cence or adulthood is causal, we evaluate the stage (older adolescence
or adulthood) at which this relationship is likely to signiﬁcant and if it
has short or long term effect in adulthood. We hypothesize that the
gateway relationship to adult drug use is transient only among older
adolescence and the relationship is modiﬁed by depressive symptoms
reported in older adolescence.
2. Materials and methods
The study sample was generated from the National Longitudinal
Study of Adolescent to Adult Health (Add Health). The Add Health
study is a national longitudinal survey of school-based representative
sample of students in grades 7–12 in 1994 academic year in the
United States. The cohort from this studywere selected and interviewed
in 1994–95 school year as in-home samples (79% response rate as a pro-
portion of selected in-home sample) forWave I (N=20,745). This sam-
ple has been followed over time with three further in-home interviews
in 1996Wave II (11–21 years, response rate 88.6%; N= 14,738), Wave
III 2001–2002 (aged 18–26 years, response rate 77.4%; N = 15,197)
with the most recent data occurring in Wave IV 2007–08 (aged
24–32 years, response rate 80.3%; N = 15,701). Our analysis used the
restricted Add Health datasets, and the detailed description of the
study design is found in other publications (Bearman et al., 1997;
Nkansah-Amankra et al., 2012). In this analysis, we a used a total sample
of 11,194 observations with complete survey weights and information
across all four waves. The study was approved by the Institutional Re-
view Board (IRB) of Central Michigan University.
2.1. Outcome measures
We used the following illegal substances fromWaves II to IV as our
outcome measures: marijuana, illicit drugs (Add Health instrument
gathered information speciﬁcally on heroin, amphetamines, LSD, PCP,
ecstasy, speed, ice to assess the illicit drugs variable) and cocaine. At
each wave of data collection, participants were asked if they had used
each of the above substances in the past 30 days. We created a
two-level outcome measure for each psychoactive substance used
from older adolescence (Wave 2) to adulthood (Waves 3 and 4).
Respondents reporting not using a substance served as the reference.
Table 1
Baseline characteristics of Add Health study participants according to early drug use,
1994–2008.
Characteristics na %b
Race
Black 2988 20.5
White 5426 61.2
Hispanic 2768 18.3
Sex
Male 4074 38.5
Female 7120 61.5
Age (years)
11–15 7716 73.7
16–19 3455 26.3
Cigarette smoking
None 4185 75.5
1–9 677 12.7
10–19 275 5.4
≥20 258 6.6
Alcohol use
None 2346 23.9
2 days or once a month 805 8.2
1–5 days in past 12 months 6740 67.8
Marijuana
None 1809 76.0
1–9 times used in past month 610 24.0
Age of onset (years) of cocaine use
None 10,546 99.4
11–15 14 0.1
16–18 74 0.6
Age of onset (years) of other illicit drugsc
None 10,094 98.3
11–15 26 0.3
16–18 160 1.4
Used mental health servicesd
No 9661 85.3
Yes 1516 14.7
a Unweighted sample distribution.
b Weighted percentage distribution.
c This variable refers to the use of LSD, amphetamines or heroin and their derivatives and
any other illicit more active psychoactive substance.
d Used ofmental health services (No=nonuse of mental health services; Yes= reported
using mental health services).
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The exposure variables of interest were the three known “gateway
substances”used in early adolescence (asmeasured inWave I): tobacco,
alcohol and marijuana. These were measured with two items, one stat-
ing if respondents had used any of these substances and the follow-up
question asking the age at which they started using each substance for
the ﬁrst time. These two items were combined to create the age of use
for the following substances: tobacco, marijuana, and alcohol as ≤10,
11–15, and 16–18 consistent with previous investigations (Tarter
et al., 2012). We were also interested in examining age of onset of illicit
drugs and Cocaine use in this age groups (≤10, 11–15, and 16–18). In a
separate analysis we speciﬁcally examined changes in the gateway drug
exposures in adolescence and changes in the pattern of illegal drug use
in adulthood.
2.3. Covariates
These include age ranges 12–19, 18–26 and 26–32 (at respective
Waves 2, 3 and 4), race (Black, White and Hispanics) and current
substance used (marijuana, illegal drugs and cocaine) at a particular
survey period to control for potential inﬂuences on early drug use and
later substance use. We used the Center for Epidemiologic Studies of
Depression (CES-D) scale as the measure of depressive symptoms and
an indicator of mental health condition (Radloff, 1977), but Waves III
and IV used only 9-items. Each response from the original item scale
was coded as 0–3 (0 = rarely or none of the time, 3 = most of the
time), and four-positively formulated items in the original scale were
reverse coded to enhance comparability in calculating the summative
score. Higher CES-D scores indicate negative emotions or negative af-
fect. The consistency of the 9-item scale in measuring depressive symp-
tomatology has been afﬁrmed in numerous studies (Levine, 2013;
Zhang et al., 2012). Across all four waves we created comparable 9-item
CES-D scales to assess depressive symptoms. Response to mental using
themental health services item in the instrument was used as a measure
of access mental health services across waves of data collection.
3. Statistical analysis
All statistical analyses were estimated using SAS Callable SUDAAN
version 9.0 (SAS Institute, Cary, NC and RTI, Cary, NC) to account for
sampling weights and other survey characteristics in determining the
standard errors. Statistical signiﬁcance for unadjusted comparisons
was assessed by using Rao Scott χ2 tests. We evaluated cohort-speciﬁc
analysis to determine the relationship between initial drug intake and
later illicit drug progression across different waves of data collection.
We estimated the odds ratios (ORs) and 95% conﬁdence intervals (CIs)
using the baseline drug use and later drug progression using the catego-
ry of non-users as the reference groups. These models were estimated
with generalized estimating equation (GEE) for repeated measures
using cumulative logit link function and simultaneously adjusting for
multiple covariates. To model the relationship between early substance
used and later substance use as exhibiting a change over time, the
variation in early exposures and changes in later drug use escalation
were examined. Analyses were 2-sided and p-values b .05 were consid-
ered statistically signiﬁcant.
4. Results
Table 1 shows the distribution of baseline mean age, age at ﬁrst sub-
stance use and other socio-demographic characteristics of Add Health
participants, 1994/95. The age group ≤15 years consistently reported
higher percent frequency distribution of substance use in Wave I.
Fig. 1 shows a box and whisker plot of depressive symptomatology
(median, 25th–75th percentiles) participants reporting using separate-
ly each gateway drug from Waves I to IV. These plots reveal strongcorrelations among cigarette smoking (60.8%) or alcohol use (38.5%)
and reporting of higher depressive symptoms over time. That is, gate-
way substance users are over time more likely to report depressive
symptoms (as measuredwith CES-D). However, both cigarette smokers
and alcohol users are over time more likely to report relatively higher
depressive symptoms than marijuana users.
Associations of baseline characteristics with psychoactive substance
use over the period of follow-up data are shown in Table 2. Age group
11–15 years or below reported the highest frequency of drug use over
time, compared to other age groups. More than three-quarters of the
sample using alcohol in Wave I (11–15 years) reported using all types
of illicit drugs over time, but a little more than half of tobacco in Wave
I used different illicit drugs. More than half of marijuana users in this
age category used marijuana a year later but the usage of other illicit
drugs was not consistent over time. Overall, illegal drugs and cocaine
in particularwere least likely to be used from adolescence to adulthood.
Relationships among various psychoactive substance uses with the
baseline age of substance use measured at 3 different survey waves
are shown in Table 3. The ﬁrst three columns of Table 3 show odds
ratio (OR) estimates and corresponding 95% conﬁdence intervals (95%
CI) for predicting drug use and mental health services access among
older adolescents. Tobacco, marijuana, any illegal drugs and age at co-
caine use in adolescence was signiﬁcantly associated with marijuana
use, illegal drugs and cocaine in older adolescence, but over time these
relationships were not consistent as expected from the gateway
hypothesis. Using marijuana at baseline appeared to be consistently
associated with increased likelihood of using other psychoactive sub-
stances in late adolescence and in young adulthood compared with
Fig. 1. The Relationship between Gateway Drugs Used and Depressive Symptoms from Adolescence to Adulthood.
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any psychoactive substances in older adolescence and over time, but to-
bacco use greatly increased the odds of usingmarijuana, cocaine and il-
legal drugs in older adolescence. Cigarette smoking greatly increased
the odds of using cocaine in early adulthood among all age groups
reporting smoking in Wave I.
The pattern consistentwith the gateway hypothesis was not present
across thewaves of data collection in to adulthood. However, among the
three gateway substances initiated in early adolescence marijuana ap-
peared somehow to have a greater and consistent effect in determining
the likelihood of using other psychoactive substances over time in
adulthood.
There were signiﬁcant interactions between the three gateway
drugs and depressive symptoms formarijuana, illegal drugs and cocaine
used in older adolescence and adulthoods (results not shown). Age
groups 11–15 years smoking cigarette inWave 1 and reporting high de-
pressive symptoms (inWave I) increased the odds of smokingmarijua-
na in older adolescence (OR = 1.37; 95% CI = 1.08, 1.74) and young
adulthood (OR= 1.54; 1.10, 2.16), whereas age groups 16–18 smoking
cigarette in Wave I and reporting high depressive symptoms in Wave 1
were at higher odds for illegal drug use in older adolescence (OR =
10.08; 95% CI = 1.59, 63.96).
Table 4 shows results from changes in the use of three gateway
drugs in adolescence and the likelihood of using illegal substances in
adulthood. Controlling for all potential confounders (race, age and cur-
rent drug use) persistent smoking in adolescence was associated with
increased odds of marijuana use in early adulthood, and marijuana
(OR = 1.47; 95% CI = 1.17, 1.83), illegal drugs (OR = 3.28; 95% CI =
2.73, 3.94) and cocaine (OR=3.70; 95% CI=3.09, 4.44) in young adult-
hood. Only heavy alcohol users were at increased odds of usingmarijuana in early adulthood and higher odds of using illegal drugs
and cocaine in young adulthood.
We next investigated whether the observed effects resulting from
the changes in the gateway drug use in adolescence and depressive
symptoms (CES-D) were consistent determinants of illegal drug use in
adulthood. Non-smokers in Waves 1 and 2 and reporting high depres-
sive symptoms inWave 3 had 1.5 times the odds of smokingmarijuana
in early (OR = 1.52: 95% CI = 1.11, 2.08) and young (OR = 1.55 95%
CI = 1.11, 2.16) adulthoods but lower risk of using illegal drugs in
early adulthood (OR= 0.29, 95% CI = 0.13, 0.66). Current smoking sta-
tus in bothwaves and reporting elevated depressive symptoms inWave
2 increases the odds of using illegal drugs in early adulthood (OR =
2.22, 95% CI = 1.12, 4.40), or smoking marijuana in young adulthood
(2.32 (95% CI = 1.52, 3.56). But those quitting smoking in Wave 2 and
reporting high depressive symptoms in Wave 2 had more than 24
times the odds of using illegal drugs in early adulthood (OR = 24.51,
95% CI = 1.87, 322.02). Individuals taking alcohol either in Wave 1 or
Wave 2 (ﬂuctuating drinkers) and reporting low depressive symptoms
in Wave 1 were at increased odds of smoking marijuana in Wave 3
(OR = 4.41; 95% CI = 1.12, 17.34).
5. Discussion
In this prospective cohort study, early use of psychoactive
substances — smoking cigarette, alcohol and illegal drugs (as earlier
deﬁned)was associatedwith increased likelihood of usingmarijuana, il-
legal drugs and to a large extent cocaine use in older adolescence. First,
early exposure to marijuana and illegal substances was also positively
associated with illegal substance and cocaine use in young adulthood.
Second, cocaine use in early adolescent appeared uniquely to have ‘a
Table 2
Distribution of population characteristics by early psychoactive drug usea among Add Health participants, baseline in 1994, follow-up in 1996–2008.
Drug use at respective wave of data collection
Wave 2 Wave 3 Wave 4
Marijuana Illegal drugsb Cocaine Marijuana Illegal drugsb Cocaine Marijuana Illegal drugsb Cocaine
Mean %†† Mean %†† Mean%†† Mean %†† Mean %†† Mean %†† Mean %†† Mean %†† Mean %††
Demographics
Mean age, years 16.6c 30.25 16.7c 6.2 16.9c 1.9 22.0c 66.9 21.8c 54.0 22.0c 52.0 28.6c 47.9 28.6c 18.1 28.6c 18.8
Age of baseline drug use
Tobacco (n = 2887; %††)
Wave 1 non-users 14.1 (408) 8.3 (55) 12.9 (19) 17.9 (338) 23.9 (72) 12.8 (39) 18.7 (253) 15.3 (195) 14.0 (187)
≤10 18.2 (411) 18.9 (93) 10.7 (21) 16.1 (271) 9.5 (67) 22.5 (56) 18.8 (261) 17.2 (234) 17.3 (237)
11–15 59.2 (1792) 66.0 (440) 71.8 (151) 67.6 (1232) 54.0 (264) 60.2 (275) 57.1 (935) 63.5 (972) 64.4 (988)
16–18 9.8 (96) 6.7 (34) 3.9 (5) 7.2 (146) 3.6 (31) 4.5 (26) 5.3 (123) 3.8 (89) 4.3 (92)
Alcohol (n = 2129; %††)
≤10 13.3 (273) 13.2 (69) 15.1 (34) 11.8 (160) 5.1 (34) 10.9 (47) 10.9 (115) 10.8 (115) 11.6 (122)
11–15 78.0 (1628) 80.4 (395) 83.0 (126) 81.6 (1049) 89.7 (241) 81.0 (224) 81.0 (814) 84.5 (858) 82.9 (840)
16–19 8.7 (228) 6.4 (38) 1.9 (3) 6.5 (110) 5.3 (34) 8.1 (25) 11.0 (115) 4.7 (80) 5.5 (82)
Marijuana (n = 3330;%††)
Wave 1 Non-users 30.5 (834) 23.5 (112) 13.0 (24) 43.8 (818) 42.5 (163) 34.1 (127) 37.7 (608) 38.7 (558) 37.3 (525)
≤10 3.4 (108) 3.5 (38) 8.5 (22) 3.2 (78) 3.1 (27) 2.5 (27) 3.2 (52) 3.4 (49) 3.7 (49)
11–15 53.8 (1534) 62.5 (413) 63.5 (130) 44.8 (893) 51.1 (209) 55.3 (197) 47.6 (714) 47.4 (717) 47.8 (757)
16–18 12.3 (396) 10.5 (59) 15.0 (17) 8.2 (196) 3.3 (34) 8.1 (44) 11.4 (195) 10.5 (161) 11.2 (169)
Any illegal drugs (3326; %††)
Non-users 79.6 (2632) 53.8 (323) 58.8 (106) 83.9 (2079) 86.0 (435) 79.5 (346) 86.4 (1710) 77.2 (1364) 80.8 (1388)
≤15 15.8 (523) 32.8 (263) 34.1 (80) 12.7 (313) 11.8 (101) 17.8 (99) 11.0 (219) 17.8 (347) 14.4 (311)
16–18 4.6 (51) 13.4 (98) 7.1 (19) 3.4 (108) 2.2 (16) 2.7 (15) 2.6 (67) 5.0 (105) 4.8 (98)
Age of cocaine use (n = 3330; %††)
Wave 1 Non-users 91.7 (2985) 80.0 (513) 72.6 (124) 92.0 (2290) 92.4 (487) 89.9 (400) 93.3 (1870) 89.0 (1614) 86.9 (1557)
≤15 5.9 (236) 12.3 (125) 17.1 (60) 6.3 (175) 5.9 (50) 7.7 (44) 5.0 (101) 8.2 (148) 9.1 (163)
16–18 2.4 (109) 7.7 (45) 10.3 (23) 1.7 (48) 1.8 (15) 2.4 (17) 1.7 (33) 2.8 (52) 4.0 (72)
Sex (n = 3359; %††)
Male 38.6 (1260) 34.6 (254) 38.6 (97) 46.7 (1106) 48.9 (261) 53.9 (235) 51.9 (1024) 48.5 (888) 50.8 (870)
Female 61.4 (2099) 65.4 (435) 61.4 (114) 53.3 (1425) 51.1 (295) 46.1 (229) 48.1 (1004) 51.5 (947) 49.2 (939)
Race (n = 3357;%††)
Black 17.1 (753) 1.9 (24) 2.3 (17) 19.4 (72) 8.7 (120) 5.1 (54) 20.6 (593) 5.6 (153) 4.4 (154)
White 60.9 (1683) 82.4 (487) 68.7 (121) 64.8 (360) 72.2 (54) 77.7 (290) 62.3 (993) 77.7 (1273) 72.1 (1161)
Hispanics 22.0 (921) 15.7 (178) 29.0 (73) 15.8 (124) 19.1 (120) 17.2 (120) 17.1 (439) 16.7 (407) 23.5 (492)
CES-D (2709; %††)
b24 41.6 (1126) 42.4 (233) 49.0 (72) 44.9 (1355) 47.3 (300) 43.5 (252) 41.7 (1201) 45.5 (1141) 44.3 (1094)
≥24 58.4 (1583) 57.6 (317) 51.0 (75) 55.1 (1311) 52.7 (278) 56.5 (225) 58.3 (1127) 54.5 (996) 55.7 (974)
Access to mental health (3359; %††)
Wave 1 non-users 80.0 (2722) 74.4 (532) 65.4 (136) 83.0 (2096) 83.1 (445) 83.0 (380) 83.8 (1707) 79.3 (1447) 81.3 (1436)
Users 20.0 (637) 25.6 (157) 34.6 (75) 17.0 (435) 16.9 (111) 17.0 (84) 16.2 (321) 20.7 (388) 18.7 (371)
Add Health = National Longitudinal of Adolescent to Adult Health; CES-D = The Center for Epidemiologic Studies Depression Scale.
n = Sample distribution of main variables and other covariates. Figure in parentheses refers to unweighted distribution and %†† describes weighted per cent distribution.
Signiﬁcant differences between groups at α= 0.05, tested using χ2 tests for categorical variables and analysis of variance for continuous variables.
†† Per cent are weighted to account for sampling weights.
a Categories shown above are not mutually exclusive.
b Illegal drugs include any type of illicit drug such as LSD, PCP, ecstasy, mushrooms, speed, ice, heroin or pills without a doctor's prescription.
c Mean age of respective drug used across different wave of data collection.
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from adolescence to adulthood, we did not observe a pattern where
early exposure to commonly known psychoactive substances —
cigarette smoking or alcohol escalates to marijuana use or illegal
psychoactive substances as posited by the ‘gateway theory.’ Finally, in-
teractions between the gateway drugs and reporting high depressive
symptoms in adolescence or adulthood were associated with increased
use of marijuana, illegal drugs and cocaine in early or young adulthood.
Our ﬁnding that early exposure to cigarette smoking and alcohol use
was positively associated with later (almost 10.4 months) use of illegal
psychoactive substances among older adolescence is consistent with
numerous studies on the gateway hypothesis (Kandel, 2002; Agrawal
et al., 2009; Mayet et al., 2012). However, our ﬁndings showed that
over a relatively longer period of time (from adolescence to adulthood),
early use of marijuana and other illegal drugs rather than tobacco or al-
cohol greatly increases the likelihood of using cocaine and other illegal
drugs. A co-twin study in Australia found early cannabis use as a consis-
tent predictor for other psychoactive substance use and in development
of drug dependence (Lynskey et al., 2003).Contrary to our ﬁndings, Tarter et al. (2012) did not ﬁnd early drug
use of gateway drugs (tobacco, alcohol) as predicting marijuana and
other illicit drug use. Participants in this study started using marijuana
before tobacco or alcohol. However, this prior ﬁnding reﬂects ease of
access to marijuana or other commonly available drugs rather than a
deﬁned pattern of drug escalation within a framework of causality.
This needs further investigations.
Our data reveal that early use of psychoactive substances is associat-
ed with increased likelihood of using further illicit substances during
adolescent period, but effects of these substances on later illicit drug
use are inconsistent. However, early use of marijuana also appears to
more readily ‘open the gate’ towards later use of other illicit substances.
These ﬁndings are remarkable in view of the current debates on legaliz-
ing marijuana for recreational and medical uses, and the fact that our
sample is population-based. Clearly, marijuana use in early adolescence
enhances increased likelihood of continuing use of other psychoactive
substances, and may be further compromised by underlying mental
health condition. Existing drug policy and intervention programs have
placed more emphases on tobacco, alcohol as ‘gateway’ drugs to later
Table 3
Adjusted odds ratios of all later psychoactive substance use (versus non-use) according to baseline characteristics amongNational Longitudinal Study of Adolescent to Adult Health (AddHealth) participants, baseline in 1994, follow-up in 1996–2008.
Drug use at respective wave of data collection
Older adolescents Early adulthood Young adulthood
Marijuana Illegal druga Cocaine Marijuana Illegal drugsa Cocaine Marijuana Illegal drugsa Cocaine
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age of baseline drug use
Tobacco
Wave 1 non-users Reference Reference Reference Reference Reference Reference Reference Reference Reference
≤10 1.92 (1.28, 2.88) 2.03 (0.96, 4.27) 2.00 (0.76, 5.23) 0.86 (0.48, 1.51) 0.28 (0.09, 0.86) 2.77 (0.73, 10.50) 0.99 (0.61, 1.62) 1.39 (0.93, 2.09) 1.46 (0.97, 2.21)
11–15 1.33 (0.99, 1.79) 1.72 (0.93, 3.18) 2.45 (1.13, 5.32) 1.07 (0.37, 1.50) 0.17 (0.06, 0.47) 3.62 (1.11, 11.79) 0.57 (0.38, 0.86) 0.92 (0.65, 1.30) 1.28 (0.90, 1.81)
16–18 2.79 (1.76, 4.44) 3.16 (1.23, 8.13) 1.24 (0.36, 4.30) 0.74 (0.37, 1.50) 0.61 (0.11, 3.22) 11.98 (1.57, 91.54) 0.50 (0.25, 0.86) 0.45 (0.25, 0.81) 0.56 (0.31, 1.00)
Alcohol
≤10 Reference Reference Reference Reference Reference Reference Reference Reference Reference
11–15 0.70 (0.45, 1.45) 0.70 (0.44, 1.10) 0.65 (0.33, 1.28) 2.34 (1.43, 3.82) 1.66 (0.73, 3.78) 2.32 (0.90, 5.96) 1.02 (0.65, 1.60) 1.00 (0.71, 1.45) 0.93 (0.63, 1.36)
16–19 0.89 (0.63, 1.25) 0.54 (0.29, 1.02) 0.11 (0.02, 0.50) 1.12 (0.57, 2.17) 0.85 (0.27, 2.70) 1.73 (0.40, 7.41) 0.67 (0.36, 1.24) 0.35 (0.20, 0.61) 0.58 (0.35, 0.96)
Marijuana Use†
Wave 1 Non-users Reference Reference Reference Reference Reference Reference Reference Reference Reference
≤10 8.36 (5.38, 13.01) 7.34 (3.64, 14.82) 32.8 (12.00, 89.70) 1.10 (0.61, 1.98) 0.56 (0.18, 1.72) 0.39 (0.14, 1.03) 1.00 (0.53, 1.87) 3.64 (1.97, 6.72) 2.86 (1.61, 5.06)
11–15 9.70 (8.27, 11.38) 7.79 (5.91, 10.28) 13.37 (6.64, 26.92) 1.43 (1.14, 1.79) 0.74 (0.50, 1.07) 1.10 (0.70, 1.73) 1.06 (0.85, 1.23) 3.19 (2.65, 3.84) 3.68 (3.06, 4.41)
16–18 9.27 (7.14, 12.04) 5.98 (3.80, 9.40) 11.80 (4.38, 31.80) 1.27 (0.86, 1.88) 0.31 (0.15, 0.67) 1.11 (0.49, 2.53) 1.22 (0.85, 1.73) 3.59 (2.65, 4.85) 4.81 (3.58, 6.47)
Any illegal drugs
Non-users Reference Reference Reference Reference Reference Reference Reference Reference Reference
≤15 5.53 (4.30, 7.11) 9.84 (7.58, 12.78) 4.29 (2.42, 7.61) 1.15 (0.62, 2.14) 0.34 (0.22, 0.53) 0.89 (0.48, 1.65) 0.76 (0.57, 1.01) 4.18 (3.28, 5.32) 1.43 (1.06, 1.92)
16–18 7.09 (4.00, 12.55) 22.30 (14.32, 34.71) 2.27 (0.98, 5.23) 1.66 (0.57, 4.88) 0.21 (0.10, 0.44) 0.14 (0.04, 0.54) 0.72 (0.45, 1.16) 5.68 (3.73, 8.66) 2.81 (1.33, 5.93)
Age of cocaine use
Wave 1 Non-users Reference Reference Reference Reference Reference Reference Reference Reference Reference
≤15 2.93 (2.11, 4.06) 4.00 (2.69, 5.96) 9.23 (5.75, 14.83) 0.75 (0.32, 1.75) 0.34 (0.15, 0.77) 0.46 (0.25, 0.87) 0.96 (0.66, 1.40) 2.62 (1.62, 4.23) 4.35 (3.21, 5.89)
16–18 3.30 (1.71, 6.37) 4.43 (2.05, 9.60) 19.64 (9.53, 40.45) 0.61 (0.22, 1.68) 0.81 (0.24, 2.74) 0.30 (0.11, 0.81) 0.40 (0.21, 0.79) 0.74 (0.39, 1.40) 13.92 (7.97, 24.29)
CES-D
Low Reference Reference Reference Reference Reference Reference Reference Reference Reference
NHigh 1.06 (0.89, 1.26) 0.97 (0.70, 1.34) 0.91 (0.52, 1.59) 0.77 (0.60, 0.99) 0.63 (0.40, 0.99) 1.32 (0.76, 2.28) 1.31 (1.03, 1.67) 0.92 (0.76, 1.12) 0.94 (0.77, 1.14)
Mental health services
Wave 1 non-users Reference Reference Reference Reference Reference Reference Reference Reference Reference
Users 1.36 (1.15, 1.63) 1.69 (1.24, 2.31) 1.48 (0.99, 2.21) 0.78 (0.62, 0.98) 0.44 (0.30, 0.65) 0.61 (0.39, 0.96) 0.75 (0.59, 0.95) 1.50 (1.23, 1.82) 1.20 (0.99, 1.47)
Abbreviations: Add Health is National Longitudinal Study of Adolescent to Adult Health; OR, odds ratio, 95% CI: 95% conﬁdence interval.
Multivariable analyses adjusted for demographic characteristics, access to mental health, and previous wave of psychoactive drug use.
Statistically signiﬁcant differences between groups at α= 0.05. Bold-faced indicate statistically signiﬁcant differences.
a Illegal drugs include any type of illicit drug such as LSD, PCP, ecstasy, mushrooms, speed, ice, heroin or pills without a doctor's prescription.
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Table 4
Adjusted odds ratios¶ and corresponding 95% conﬁdence intervals of changes occurring in using drugs in early or young adulthood among respondents participating in the National
Longitudinal Study of Adolescent Health (Add Health), 1994–2008.
Early adulthooda Young adulthoodb
Marijuana Illegal drug use Cocaine Marijuana Illegal drugs Cocaine
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Exposure changes in Waves 1–2
Tobacco use
Non-smokers Reference Reference Reference Reference Reference Reference
Persistent smokers 1.96 (1.56, 2.45) 0.87 (0.57, 1.28) 1.28 (0.79, 2.08) 1.47 (1.17, 1.83) 3.28 (2.73, 3.94) 3.70 (3.09, 4.44)
New onset 3.48 (1.22, 9.91) 6.73 (1.39, 32.61) 1.31 (0.28, 6.08) 0.67 (0.27, 1.69) 1.27 (0.59, 2.70) 1.54 (0.76, 3.11)
Quitters 0.99 (0.71, 1.38) 0.29 (0.11, 0.78) 0.39 (0.16, 0.95) 0.91 (0.64, 1.28) 0.99 (0.72, 1.36) 0.93 (0.67, 1.29)
Alcohol use
Non-users Reference Reference Reference Reference Reference Reference
Heavy drinkers 1.69 (1.21, 2.37) 0.45 (0.24, 0.86) 1.88 (0.92, 3.85) 0.96 (0.69, 1.33) 1.93 (1.45, 2.57) 1.56 (1.20, 2.04)
Moderate users 1.30 (0.73, 2.32) 0.28 (0.11, 0.70) 0.99 (0.30, 3.24) 0.69 (0.38, 1.22) 1.96 (1.22, 3.13) 1.86 (1.18, 2.94)
Fluctuate/relapse 1.18 (0.92, 1.92) 0.45 (0.16, 1.27) 0.89 (0.24, 3.24) 0.59 (0.35, 0.98) 1.33 (0.85, 2.09) 0.49 (0.30, 0.80)
Marijuana use
Non-users Reference Reference Reference Reference Reference Reference
1–19 1.05 (0.59, 1.87) 1.31 (0.49, 3.55) 1.41 (0.38, 5.22) 2.50 (1.45, 4.31) 2.14 (1.30, 3.52) 2.50 (1.45, 4.31)
≥20 0.73 (0.28, 1.90) 0.92 (0.20, 4.21) 0.35 (0.06, 2.17) 1.20 (0.50, 2.86) 8.07 (4.10, 15.90) 1.20 (0.50, 2.86)
Irregular (1 or ≥20) 1.10 (0.74, 1.64) 1.78 (0.82, 3.87) 0.89 (0.36, 2.18) 1.47 (1.02, 2.13) 1.94 (1.37, 2.74) 1.47 (1.02, 2.13)
Abbreviations: CI = conﬁdence interval; OR, odds ratio; Add Health.
CES-D is Center for Epidemiologic Study of Depression Scale.
§Initial drug use refers to use of tobacco, alcohol, marijuana (gateway drugs) at baseline of the study, in the early adolescence. Reference group is non-users of a particular gateway drug at
the respective developmental stage.
¶ Adjusted for the following covariates at different exposures: age, gender, race,
a Young adulthood (age groups 19-23 years).
b Older adulthood (age groups 24-33 years).
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placed on marijuana and other psychoactive substances in some
population groups particularly in the age groups ≤15.
Our ﬁndings also reveal that it is not solely early exposure to psy-
choactive substances that matters for later drug use, but also the
timing of the exposure to these ‘gateway drugs.’ For some illegal
drug use outcomes, particularly those related to marijuana use, alcohol
and to some extent tobacco exposures in adolescencemay be especially
harmful in young adulthood. Both heavy and moderate users of alcohol
as well as adolescents using marijuana (of different amounts) inWaves
I and II were at increased odds of using illegal drugs and cocaine in
young adulthood. The construct of “gateway theory” or GH has some
heuristic and intuitive appeal to the academics, policy makers and the
general public. The idea of gateway substance use among adolescents
actually assumes that once consumption of psychoactive substance
is initiated the trend is to escalate and suggests that adolescent be-
haviors are immutable. Even though this is appealing, the idea is
inconsistent with age-related reductions in drug use observed in
the human development phenomenon described as ‘maturing out’
(Lee et al., 2013) during emergent adulthood (Littleﬁeld et al.,
2009).
Strengths of this study include the length (≥14 years) of the Add
Health data and the sampling procedure used allowed prospective
analyses of variations in different psychoactive drugs used from early
adolescence to young adulthood. Availability and inclusion of current
drugs used in statistical models across each wave enabled ascertain-
ment of effects of earlier drugs used on current illicit drugs (while
controlling for previous drugs). Given the relatively large sample size,
wewere able tomodel changes in drug use during adolescence and like-
lihood of using other drugs in adulthood — a feature that has not been
applied in numerous studies. Another unique contribution of this
study was analyses of interactive effects among early drug use, depres-
sive symptoms (mental illness) on the risk of later drug use in adult-
hood, features which were not available in other studies. However,
our study has some limitations. First, the taxonomy used in classifying
drugs is purely based on the legal status, and social acceptability, not
necessarily on the basis of the inherent harm each is likely to cause.
Ideally, classifying drugs on dimensions of harmfulness or increasedlikelihood of addiction and potential size of a threat to the individual
and the larger society should be the focus of future investigations.
Second, we could not measure amounts of early psychoactive sub-
stances that precipitated the use of ‘hard and illicit’ drugs over time. It
is almost impossible to evaluate or predict with certainty the quantity
of each psychoactive substance(s) needed to achieve these changes.
Third, our study could not also examine other psychological and patho-
logical variables associated with early or continuing drug use. In partic-
ular, it is not clear whether individuals using marijuana to reduce
anxiety in social circumstances such as to avoid certain negative social
affects (Buckner et al., 2011). Fourth, if unobserved environmental or
genetic factors are associated with early psychoactive substance use
and follow-ups, then our model estimations might be biased, and in
that case itmight be inappropriate to assume that later druguse is solely
attributable to early drug use. Finally, historical and secular trends oc-
curring in the use of licit or illicit substances in the country might sug-
gest that describing substance use in terms of onset might be too
simplistic because such an account might not consider substance use
history over time.6. Conclusion
In conclusion, this study did not ﬁnd that the proportion of the pop-
ulation using alcohol, tobacco ormarijuana in early adolescence showed
patterns of increasing use of marijuana, illegal drugs or cocaine accord-
ing to the length of follow-up (approximately 14 years). These ﬁndings
suggest that adolescent drug prevention and treatment programs
should apply proven multi-sectoral prevention strategies rather than
providing brief counseling methods only on individual behaviors.
While individual behavior change is desirable, a focus on the individual
may be inconsequential compared to radical changes that may need to
be made at the broader societal contexts. In addition, such efforts
must not only focus on licit substances but includemarijuana and assess
the underlying mental illness predisposing young people to early drug
use. In particular adolescents' recreational use of marijuana needs to
be discouraged at the earliest age and medical marijuana use must
have strict adherence to treatment regimen.
141S. Nkansah-Amankra, M. Minelli / Preventive Medicine Reports 4 (2016) 134–141References
Agrawal, A., Lynskey, M.T., Madden, P.A.F., Pergadia, M.L., Bulchoz, K.K., Heath, A.C., 2009.
Simultaneous cannabis and tobacco use and cannabis-related outcomes in young
women. Drug Alcohol Depend. 101, 8–12.
Bearman, P.S., Jones, J., Udry, J.R., 1997. The National Longitudinal Study of Adolescent
Health: Research Design Available via internet at: http://www.cpc.unc.edu/addhealth.
Behrendt, S.,Wittchen, H.-U., Höﬂer, L.R., Beesdo, K., 2009. Transitions from ﬁrst substance
use to substance use disorders in adolescence: is early onset associated with a rapid
escalation? Drug Alcohol Depend. 99, 68–78.
Buckner, J.D., Silgado, J., Schmidt, N.B., 2011. Marijuana craving during a public speaking
challenge: understanding marijuana use vulnerability among women and those
with social anxiety disorder. J. Behav. Ther. Exp. Psychiatry 42, 104–110.
Chen, C.-Y., Storr, C.L., Anthony, J.C., 2009. Early-onset drug use and risk for drug
dependence problems. Addict. Behav. 34, 319–322.
Degenhardt, L., Dierker, L., Chiu, W.T., et al., 2010. Evaluating the drug use “gateway”
theory using cross-national data: consistency and associations of the order initiation
of drug use among participants in the WHO World Mental Surveys. Drug Alcohol
Depend. 108, 84–97.
Deza, M., 2015. Is there a stepping stone effect in drug use? Separating state dependence
from unobserved heterogeneity within and between illicit drugs. J. Econ. 184,
193–207.
Fairman, B.J., 2015. Cannabis problem experiences among users of the tobacco-cannabis
combination known as blunts. Drug Alcohol Depend. 150, 77–84.
Fergusson, D.M., Boden, J.M., Horwood, L.J., 2006. Cannabis use and other illicit drug use:
testing the cannabis gateway hypothesis. Addiction 101, 556–569. http://dx.doi.org/
10.1111/j.1360-0443.2005.01322.x.
Golub, A., Johnson, B., 1994. The shifting importance al alcohol and marijuana as gateway
substances among serious drug abusers. J. Alcohol 55, 607–614.
Guerra, L.S., Romano, P.S., Samuels, S.J., Kass, P.H., 2000. Ethnic differences in adolescent
substance initiation sequences. Arch. Pediatr. Adolesc. Med. 154, 1089–1095.
Gundy, K.V., Rebellon, C.J., 2010. A life course perspective on the "Gateway Hypothesis.
J. Health Soc. Behav. 51 (3), 244–259.
Guxens, M., Nebot, M., Ariza, C., 2007. Age and sex differences in factors associated with
the onset of cannabis use: a cohort study. Drug Alcohol Depend. 88, 234–243.
Kandel, D., 1975. Stages in adolescent involvement in drug use. Science 190, 912–914.
Kandel, D., 2002. Stages and Pathways of Drug Involvement: Examining the Gateway
Hypothesis. Cambridge University Press, Cambridge, England.
Kandel, D.P., Faust, R., 1975. Sequence and stages in patterns of adolescent drug use. Arch.
Gen. Psychiatry 32, 923–932.
Kandel, E.R., Kandel, D.B., 2014. A molecular basis for nicotine as a gateway drug. N. Engl.
J. Med. 371 (10), 932–943.
Kandel, D.B., Yamaguchi, K., Chen, K., 1992. Stages of progression in drug involvement
from adolescence to adulthood: further evidence for the gateway theory. J. Stud.
Alcohol 53, 447–457.Kirby, T., Barry, A.E., 2012. Alcohol as a gateway drug: a study of U.S. 12th graders. J. Sch.
Health 82, 371–379.
Korhoene, T., Prince van Leeuven, A., Rejneveld, S.A., Ormel, J., Verhulst, F.C., Huizinc, A.C.,
2010. Externalizing behavior problems and cigarette smoking as predictors of cannabis
use: the TRAILS study. J. Am. Acad. Child Adolesc. Psychiatry 49, 61–69.
Lee, M.R., Chassin, L., Villalta, I.K., 2013. Maturing out of alcohol involvement: transitions
in latent drinking statuses from late adolescence to adulthood. Dev. Psychopathol. 25,
1137–1153.
Lessem, J., Hopfer, C., Haberstick, B., et al., 2006. Relationship between adolescent
marijuana use and young adult illicit drug use. Behav. Genet. 36, 4.
Levine, S.Z., 2013. Evaluating the seven-item Center for Epidemiologic Studies Depression
Scale short form: a longitudinal US community study. Soc. Psychiatry Psychiatr.
Epidemiol. 48, 1519–1526.
Littleﬁeld, A.K., Sher, K.J., Wood, P.K., 2009. Is “maturing out” of problematic alcohol
involvement related to personality change? J. Abnorm. Psychol. 118, 360–374.
Lynskey, M.T., Heath, A.C., Bucholz, K.T., et al., 2003. Escalation of drug use in early-onset
cannabis users vs co-twin controls. J. Am. Med. Assoc. 289, 427–433.
Mackesy-Amiti, M.E., Frendrich, M., Goldstein, P.J., 1997. Sequence of drug use among se-
rious drug users: typical vs atypical progression. Drug Alcohol Depend. 45, 185–196.
Mayet, A., Legleye, S., Falissard, B., Chau, N., 2012. Cannabis use stages as predictors of
subsequent initiation with other illicit drugs among French adolescents: use of a
multi-state model. Addict. Behav. 37, 60–166. http://dx.doi.org/10.1016/j.addbeh.
2011.09.012.
Midanik, L.T., Tam, T.W., Weisner, C., 2007. Concurrent and simultaneous drug and alco-
hol use: results of the 2000 National Alcohol Survey. Drug Alcohol Depend. 90, 72–80.
Morral, A.R., McCaffrey, D.F., Paddock, S.M., 2002. Reassessing marijuana gateway effect.
Addiction 97, 1493–1504.
Nkansah-Amankra, S., Diedhiou, A., Agbanu, S.K., et al., 2012. A longitudinal evaluation of
religiosity and psychosocial determinants of suicidal behaviors among a population-
based sample in the United States. J. Affect. Disord. 139, 40–51.
Radloff, L.S., 1977. The CES-D Scale. A self-report depression scale for research in the gen-
eral population. Appl. Psychol. Meas. 1, 385–401.
Tarter, R.E., Kirisci, L., Mezzich, A., et al., 2012. Does the “gateway” sequence increase pre-
diction of cannabis use disorder development beyond deviant socialization? Implica-
tions for prevention practice and policy. Drug Alcohol Depend. 123S, S72–278.
Trenz, R., Scherer, M., Harrell, P., Zur, J., Sinha, A., Latimer, W., 2012. Early onset of drug
and polysubstance use as predictors of injection drug use among adult drug users.
Addict. Behav. 37, 367–372.
Zhang, W., O'Brien, N., Forrest, J.I., et al., 2012. Validating a shortened depression scale (10
item CES-D) among HIV-positive people in British Columbia, Canada. PLoS ONE 7,
e40793–e40801.
